Physicians and the pharmaceutical industry: Is a gift ever just a gift?

JAMA

Volumn 283, Issue 3, 2000, Pages 373-380

  Wazana, Ashley ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUING EDUCATION; DRUG INDUSTRY; DRUG MARKETING; MEDICAL ETHICS; MEDICAL RESEARCH; MEDICAL SCHOOL; MEDICAL STUDENT; PHYSICIAN; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REVIEW;

EID: 0034684955     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.3.373     Document Type: Review

References (64)

1. Erola JA. We need dialogue and discussion, not a new Berlin Wall. CMAJ. 1994;150:955-956.
2. Guyatt G. Academic medicine and the pharmaceutical industry. CMAJ 1994;150:951-953.
3. Waud DR. Pharmaceutical promotions a free lunch? N Engl J Med. 1992;327:351-353.
4. Woollard RF. Addressing the pharmaceutical industry's influence on professional behaviour. CMAJ. 1993;149:403-404.
5. Wolfe SM. Why do American drug companies spend more than $12 billion a year pushing drugs? J Gen Intern Med. 1996;11:637-639.
6. Woosley RL. Centers for education and research in therapeutics. Clin Pharmacol Ther. 1994;55:249.
7. Drake D, Uhlman M. Making Medicine, Making Money. Kansas City, Mo: Andrews & McMeel; 1993.
8. Randall T. Kennedy hearings say no more free lunch - or much else - from drug firms. JAMA. 1991; 265:440, 442.
9. Palmisano P, Edelstein J. Teaching drug promotion abuses to health profession students. J Med Educ. 1980;55:453-455.
10. Hemminki E. Review of literature on the factors affecting drugprescribing.Soc Sci Med. 1975;9:111-116.
11. Smith MC. Drug product advertising and prescribing. Am J Hosp Pharm. 1977;34:1208-1224.
12. Lexchin J. Interactions between physicians and the pharmaceutical industry. CMAJ. 1993;149:1401-1407.
13. Medical Lobby for Appropriate Marketing. Bibliography on pharmaceutical promotion. Available at: http://www.camtech.net.au/malam/bibliogr.htm. Accessed December 13, 1999.
14. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988;8:13-20.
15. Spingarn RW, Berlin JA, Strom BL. When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? Acad Med. 1996;71:86-88.
16. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. Chest. 1992;102:270-273.
17. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies. JAMA. 1994;271:684-689.
18. Bowman MA. The impact of drug company funding on the content of continuing medical education. Mobius. 1986;6:66-69.
19. Gibbons RV, Landry FJ, Blouch DL, et al. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. J Gen Intern Med. 1998; 13:151-154.
20. Sandberg WS, Carlos R, Sandberg EH, Roizen MF. The effect of educational gifts from pharmaceutical firms on medical students' recall of company names or products. Acad Med. 1997;72:916-918.
21. Mahood S, Zagozeski C, Bradel T, Lawrence K. Pharmaceutical policies in Canadian family medicine training. Can Fam Physician. 1997;43:1947-1951.
22. Hopper JA, Speece MW, Musial JL. Effects of an educational intervention on residents' knowledge and attitudes toward interactions with pharmaceutical representatives. J Gen Intern Med. 1997;12:639-642.
23. Sergeant MD, Hodgetts PG, Godwin M, Walker DM, McHenry P. Interactions with the pharmaceutical industry. CMAJ. 1996;155:1243-1248.
24. Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives and the cost of prescribing. Arch Fam Med. 1996;5:201-206.
25. Strang D, Gagnon M, Molloy W, et al. National survey of the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives. Ann R Coll Physicians Surg Can. 1996:29:474-478.
26. Hodges B. Interactions with the pharmaceutical industry. CMAJ. 1995;153:553-559.
27. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995;273:1296-1298.
28. Andaleeb SS, Tallman RF. Physician's attitudes toward pharmaceutical sales representatives. Health Care Manage Rev. 1995;20:68-76.
29. Poirier TI, Giannetti V, Giudici RA. Pharmacists' and physicians' attitudes toward pharmaceutical marketing practices. Am J Hosp Pharm. 1994;51:378-381.
30. Thomson AN, Craig BJ, Barham PM. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. Br J Gen Pract. 1994;44:220.
31. Brotzman GL, Mark DH. The effect on resident attitudes of regulatory policies regarding pharmaceutical representative activities. J Gen Intern Med. 1993; 8:130-134.
32. Reeder M, Dougherty J, White LJ. Pharmaceutical representatives and emergency medicine residents. Ann Emerg Med. 1993;22:105-108.
33. Keim SM, Sanders AB, Witzke DB, Dyne P, Fulginiti JW. Beliefs and practices of emergency medicine faculty and residents regarding interactions with the biomedical industry. Ann Emerg Med. 1993;22: 1576.
34. Banks JW III, Mainous AG III. Attitudes of medical school faculty toward gifts from the pharmaceutical industry. Acad Med. 1992;67:610-612.
35. Brotzman GL, Mark DH. Policies regulating the activities of pharmaceutical representatives in residency programs. J Fam Pract. 1992;1:54-57.
36. Bucci KK, Frey KA. Involvement of pharmacy faculty in the development of policies for pharmaceutical sales representatives. J Fam Pract. 1992;34:49-52.
37. Lichstein PR, Tumer RC, O'Brien K. Impact of pharmaceutical company representatives on internal medicine residency programs. Arch Intern Med. 1992;152: 1009-1013.
38. McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, Rich EC. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA. 1990;264:1693-1697.
39. Lurie N, Rich EC, Simpson DE, et al. Pharmaceutical representatives in academic medical centers. J Gen Intern Med. 1990;5:240-243.
40. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 1988; 26:1183-1189.
41. Bower AD, Burkett GL. Family physicians and generic drugs. J Fam Pract. 1987;24:612-616.
42. Haayer F. Rational prescribing and sources of information. Soc Sci Med. 1982;16:2017-2023.
43. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonist. N Engl J Med. 1998;338:101-106.
44. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med. 1996;124:485-489.
45. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal antiinflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994;154:157-163.
46. Anderson JJ, Felson DT, Meenan RF. Secular changes in published clinical trials of second-line agents in rheumatoid arthritis. Arthritis Rheum. 1991;34:1304-1309.
47. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med. 1986;1:155-158.
48. Hill AB. The environment and disease. Proc R Soc Med. 1965;58:295-300.
49. Landefeld CS, Chren MM. Drug companies and information about drugs: recommendations for doctors. J Gen Intern Med. 1996;11:642-644.
50. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73:4-8.
51. Hemminki E. Content analysis of drug-detailing by pharmaceutical representatives. Med Educ. 1977; 11:210-215.
52. Wade VA, Mansfield PR, McDonald PJ. Drug companies' evidence to justify advertising. Lancet. 1989; 2:1261-1263.
53. Canadian Medical Association. Physicians and the pharmaceutical industry (update 1994). CMAJ. 1994; 150:256A-256F.
54. Royal College of Physicians and Surgeons of Canada. Guidelines for support of continuing medical education by industry. Available at: http:// rcpsctest.medical.org/english/public/policy/ cme_e.html. Accessed December 8, 1999.
55. Council on Ethical and Judicial Affairs, American Medical Association. Gifts to physicians from industry. JAMA. 1991;265:501.
56. Guidelines for faculty involvement in commercially supported continuing medical education. Acad Med. 1992;67:615-621.
57. American College of Physicians. Physicians and the pharmaceutical industry. Ann Intern Med. 1990; 112:624-626.
58. Bickell NA. Drug companies and continuing medical education. J Gen Intern Med. 1995;10:392-394.
59. Anastasio GD, Little JM. Pharmaceutical marketing. Pharmacotherapy. 1996;16:103-107.
60. Daniel EE, Leedham L. Effect on student attitudes of a program of critical evaluation of claims for drugs. J Med Educ. 1966;41:49-60.
61. Ferguson RP. Training the resident to meet the detail men. JAMA. 1989;261:992-993.
62. Shear NH, Black F, Lexchin J. Examining the physician-detailer interaction. Can J Clin Pharmacol. 1996; 3:175-179.
63. Berings D, Blondeel L, Habraken H. The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice. Eur J Clin Pharmacol. 1994;46:501-505.
64. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care. Milbank Q. 1989; 67:268-317.